FDA Cancer Office Taps Syapse for Real-world Evidence Development
The two plan to tap multiple data sources, including from electronic health records, registries and more, plus molecular diagnostic data.
By Conor Hale | Aug 14, 2019 | FierceBiotech
Healthcare data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

Syapse and the FDA will explore the use of real-world endpoints for cancer treatments such as the clinical impacts of molecular testing. (FDA)
The multiyear research collaboration with the FDA’s Oncology Center of Excellence will have a special focus on precision medicine and the evaluation of targeted therapies. In addition, Syapse and agency staff aim to build a framework for answering key regulatory questions regarding potential cancer therapies’ safety, dosing and patient outcomes, as well as ways to identify patterns in testing and treatment.
“Advances in real-world evidence present an opportunity to learn from patients and potentially translate those insights into safer and more effective therapies,” the FDA’s Sean Khozin, associate director for oncology regulatory science and informatics, said in a statement.
“Real-world evidence from well-designed studies meeting appropriate data quality standards can help to inform decision-making and provide information regarding the impact of new therapies in real-world patient populations, particularly those not represented in clinical trials,” Khozin added. “This is especially critical in precision medicine, where understanding all of the factors that may drive safety and response is both imperative and difficult to capture at scale using traditional clinical trials.”
Syapse and the FDA will also explore the use of real-world endpoints for cancer treatments, such as the clinical impact of molecular testing, as well as the incorporation of patient-reported outcomes into real-world evidence. The two plan to tap multiple data sources, including from electronic health records, registries and more, plus molecular diagnostic data.
“Advancing a deeper understanding of real-world endpoints and analytical methodologies is critical to assuring that all stakeholders can have confidence in the quality of evidence produced and accelerating the use of RWE in regulatory decision-making,” said Syapse founder and President Jonathan Hirsch.
Syapse recently inked a deal with Pfizer to help provide precision medicine data gathering and real-world outcomes research for its work in cancer, focusing on the factors that may influence oncologists as they choose different molecular testing and therapy strategies for different patients.
TRNDS 2019
University of Rochester
Saunders Research Building
Helen Wood Hall Auditorium
255 Crittenden Blvd
Rochester, NY 14642
Date: Friday, September 13
Time: 7:30 am – 4:00pm
TRNDS News
Sign-up for TRNDS updates and rare disease news
-
New Grants will Accelerate Clinical Trials in Rare Neurological Disorders
-
Neurogene Offers Access to Genetic Testing for Lysosomal Storage Disease
-
NIH launches 5-year, $10 million study on acute flaccid myelitis
-
Study refines ALS risk among first-degree relatives of patients with disease
-
NCATS Director Warns of 'Poorly Understood Public Health Implications of Rare Diseases'
-
Speeding Up Drug Discovery for Brain Diseases
-
NIH-Funded Project Aims to Build a ‘Google’ for Biomedical Data
-
Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
-
(Podcast) Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics
-
Meet TRNDS 2019 Speaker PJ Brooks
-
Rare Pediatric Disease PRVs: FDA Updates Guidance
-
Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
-
C-Path and NORD Collaborate to Launch Rare Disease Data Platform
-
Meet TRNDS Speaker Tauna Batiste
-
HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials
-
Evidation & Eli Lilly Study Uses Apple Devices, Apps to Predict Cognitive Impairment
-
'Dr. Google' Helps Some Patients Diagnose a Rare Disease
-
Antisense Drugs for HD, ALS & Prion Could Meet the Need for Brain Treatments
-
Ultragenyx Partners with GeneTx to Advance Treatment for Angelman Syndrome
-
Netflix's Medical Investigation Docuseries 'Diagnosis'
-
NIH All of Us Project Tops 270,000 Sign-ups
-
FDA Cancer Office Taps Syapse for Real-world Evidence Development
-
Gene Linked to Rare Neurological Disorder May Play a Role in Alzheimer’s
-
Gene Therapy Developers Issue Principles for Human Genome Editing
-
Forget Single Genes: CRISPR Now Cuts & Splices Whole Chromosomes
-
TRNDS Speaker Benjamin Schlatka, MC10
-
TRNDS Speaker Danielle Edwards, Jett Foundation
-
His daughter has a rare disorder. He’s developing a novel gene therapy.
-
A Doctor Tested a New Treatment on Himself, Now it's Saving Other Lives
-
Study Presents Clinical, Genetic Landscape of Pompe Disease
Room Block
Hilton Garden Inn
Rochester/University
Medical Center
30 Celebration Drive
Rochester, NY 14620
Phone: 585-424-4404
TRNDS Rate: $149/night